Cargando…

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

The mechanisms underlying the resistance to immune checkpoint inhibitors (ICIs) therapy in metastatic urothelial carcinoma (mUC) patients are not clear. It is of great significance to discern mUC patients who could benefit from ICI therapy in clinical practice. In this study, we performed machine le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Siteng, Zhang, Ning, Wang, Tao, Zhang, Encheng, Wang, Xiang, Zheng, Junhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477044/ https://www.ncbi.nlm.nih.gov/pubmed/32983112 http://dx.doi.org/10.3389/fimmu.2020.01900

Ejemplares similares

Robust Prediction of Prognosis and Immunotherapeutic Response for Clear Cell Renal Cell Carcinoma Through Deep Learning Algorithm
por: Chen, Siteng, et al.
Publicado: (2022)

A Novel m(6)A Gene Signature Associated With Regulatory Immune Function for Prognosis Prediction in Clear-Cell Renal Cell Carcinoma
por: Chen, Siteng, et al.
Publicado: (2021)

A novel ferroptosis-related gene signature associated with cell cycle for prognosis prediction in patients with clear cell renal cell carcinoma
por: Chen, Siteng, et al.
Publicado: (2022)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
por: Chiang, Ryan S., et al.
Publicado: (2020)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors
por: Yang, Ximing, et al.
Publicado: (2022)

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Hong, Joohyun, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

A Novel Nomogram Based on Machine Learning-Pathomics Signature and Neutrophil to Lymphocyte Ratio for Survival Prediction of Bladder Cancer Patients
por: Chen, Siteng, et al.
Publicado: (2021)

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
por: Houssiau, Hélène, et al.
Publicado: (2022)

Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors
por: Jiang, Shuai, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers
por: Wang, Jingting, et al.
Publicado: (2022)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
por: Dermime, Said, et al.
Publicado: (2021)

Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
por: Guo, Ya, et al.
Publicado: (2022)

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors
por: Lavoie, Jean-Michel, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer
por: Zhu, Alec, et al.
Publicado: (2023)

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy
por: Pickering, Chad, et al.
Publicado: (2023)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
por: Naito, Renato, et al.
Publicado: (2020)

Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma
por: Su, Ruopeng, et al.
Publicado: (2023)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
por: Zhong, Yu-Min, et al.
Publicado: (2022)

Clinical use of machine learning‐based pathomics signature for diagnosis and survival prediction of bladder cancer
por: Chen, Siteng, et al.
Publicado: (2021)

Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma
por: Feng, Wenqin, et al.
Publicado: (2022)

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer
por: Xu, Chao, et al.
Publicado: (2023)

Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2023)

Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma
por: Brown, Jason R., et al.
Publicado: (2021)

Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints
por: Wang, Xiaoqiang, et al.
Publicado: (2023)

Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine
por: Sun, Zhuolun, et al.
Publicado: (2023)

First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis
por: Lin, Chang-Ting, et al.
Publicado: (2022)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma
por: Seront, Emmanuel, et al.
Publicado: (2018)

Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma—A Review
por: Walia, Arman S., et al.
Publicado: (2021)

Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
por: Mohr, Raphael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_isc7m7k4gadrt5moo1qsdi8m9l